Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Capital Expenditures (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Capital Expenditures for 13 consecutive years, with -$53000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 120.7% year-over-year to -$53000.0, compared with a TTM value of $283000.0 through Dec 2025, down 10.73%, and an annual FY2025 reading of $283000.0, down 10.73% over the prior year.
  • Capital Expenditures was -$53000.0 for Q4 2025 at Agios Pharmaceuticals, up from -$1.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $5.3 million in Q4 2021 and bottomed at -$2.8 million in Q2 2022.
  • Average Capital Expenditures over 5 years is $611050.0, with a median of $127000.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures skyrocketed 46633.33% in 2022, then crashed 6968.42% in 2025.
  • Year by year, Capital Expenditures stood at $5.3 million in 2021, then plummeted by 97.85% to $113000.0 in 2022, then surged by 771.68% to $985000.0 in 2023, then crashed by 74.01% to $256000.0 in 2024, then plummeted by 120.7% to -$53000.0 in 2025.
  • Business Quant data shows Capital Expenditures for AGIO at -$53000.0 in Q4 2025, -$1.3 million in Q3 2025, and $1.4 million in Q2 2025.